Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, ...

Lumipulse proved successful in a clinical trial. Before earning FDA clearance, a clinical trial tested the blood samples of 499 cognitively impaired adults to evaluate them for Alzheimer’s disease.

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans ... The FDA has approved two Alzheimer's drugs targeting amyloid plaques in adults with ...

The FDA has cleared Lumipulse, the first-ever blood test for early Alzheimer's detection, reducing the need for costly and invasive procedures.

The US Food and Drug Administration (FDA) has granted 510(k) clearance to the first blood test to aid in diagnosing Alzheimer’s disease (AD). The Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma ...

The FDA found that the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is substantially equivalent to the Lumipulse G β-amyloid Ratio (1-42/1-40), ...

The FDA has approved the first blood test to detect signs of Alzheimer’s disease, marking a major step toward easier diagnosis. The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test ...

Fujirebio's test works with the company's Lumipulse equipment, which the company says is already "widely available in clinical laboratories" around the U.S. Fujirebio describes Lumipulse as a ...

The test is called the “Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio” and is developed by the Japanese company Fujirebio Diagnostics… The Food and Drug Administration (FDA) ...